The Impact Of A Molecular Tumor Board On Treatment Decisions For 35 Patients: The Dartmouth Experience.

1550 Background: Genetic profiling of tumors is a powerful approach to predict drug sensitivity and resistance. However, oncologists are often unfamiliar with interpretation of genetic data. We established a Molecular Tumor Board (MTB) at our Cancer Center to interpret individual patients’ tumor genetic profiles and provide treatment recommendations. Methods: DNA from tumor specimens was sequenced in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory to identify coding mutations in a 50-gene panel (n= 34), or a 255-gene panel (n= 1). Cases were evaluated by a MTB composed of molecular and anatomic pathologists, medical oncologists, basic research scientists, and genetic counselors. Results: Thirty-five cases were evaluated in one year by the MTB. The most common reason for MTB referral was a request for recommendations on targeted therapies (91.9%), and for potential germline mutations. Tumors exhibited a wide range of genetic heterogeneity: 71 different mutations were found across 3...